DDInter770 DDInter899
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Fluvoxamine {u} (Compound) resembles {v} (Compound) Ridogrel
Fluvoxamine {u} (Compound) binds {v} (Gene) CYP3A4
Fluvoxamine {u} (Compound) upregulates {v} (Gene) CCNA1
Fluvoxamine {u} (Compound) palliates {v} (Disease) endogenous depression
Fluvoxamine {u} (Compound) downregulates {v} (Gene) HERPUD1
Fluvoxamine {u} (Compound) causes {v} (Side Effect) Accommodation disorder
Fluvoxamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Fluvoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Fluvoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tenecteplase
Fluvoxamine {u} may lead to a major life threatening interaction when taken with {v} Phenylpropanolamine
Fluvoxamine (Compound) resembles Ridogrel (Compound)
Fluvoxamine (Compound) binds CYP3A4 (Gene)
Fluvoxamine (Compound) upregulates CCNA1 (Gene)
Fluvoxamine (Compound) palliates endogenous depression (Disease)
Fluvoxamine (Compound) downregulates HERPUD1 (Gene)
Fluvoxamine (Compound) causes Accommodation disorder (Side Effect)
Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase
Fluvoxamine may lead to a major life threatening interaction when taken with Phenylpropanolamine